RA0538

antibody from Oursmab

Targeting: OLR1 CLEC8A, LOX-1, SCARE1

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0538

Provider

Oursmab

Product name

Golocdacimab (Biosimilar Reference Antibody) (OLR1)

Antibody type

Monoclonal

Description

Golocdacimab (development code MEDI6570) is an investigational, fully human monoclonal antibody being developed for the potential treatment of cardiometabolic diseases, specifically type 2 diabetes (T2D) and its associated complications. It functions as a targeted inhibitor of Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). By binding with high affinity to LOX-1, golocdacimab blocks its interaction with its primary ligand, oxidized low-density lipoprotein (oxLDL). This blockade aims to inhibit the LOX-1-mediated signaling cascade that contributes to endothelial dysfunction, vascular inflammation, and atherogenesis¡ªpathological processes that are accelerated in type 2 diabetes and drive cardiovascular risk.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.